Healthcare / Medical DevicesNasdaqGM
$16.82
+0.18 (+1.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-41.3M · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$432M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.4%
↓Gross Margin
73.1%
↑Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
+22.5%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $236.3M · net income $-39.6M · FCF $-16.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $236.3M | $236.3M | $204.7M | $148.7M | $122.3M | $98.0M | $71.1M | $72.6M | $57.6M | $45.6M | $37.3M | $31.0M |
| Net Income | $-39.6M | $-39.6M | $-37.8M | $-21.0M | $1.3M | $-16.3M | $-32.9M | $-13.7M | $-12.0M | $-8.9M | $-6.6M | $-7.9M |
| EBITDA | $-7.9M | $-7.9M | $-10.4M | $-8.4M | $-8.7M | $-7.3M | $-18.7M | $-4.4M | $-6.7M | $-4.1M | $-4.2M | $-4.7M |
| EPS | -1.69 | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -0.94 | — | — | — | — |
| Gross Margin | 73.1% | 73.1% | 72.6% | 74.8% | 74.1% | 74.9% | 77.4% | 75.3% | 74.2% | 75.5% | 70.7% | 69.8% |
| Operating Margin | -12.3% | -12.3% | -14.4% | -17.3% | -17.8% | -18.4% | -37.6% | -12.5% | -16.6% | -14.2% | -16.4% | -21.3% |
| Net Margin | -16.8% | -16.8% | -18.5% | -14.1% | 1.0% | -16.6% | -46.3% | -18.9% | -20.9% | -19.6% | -17.6% | -25.5% |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.29 | 0.29 | 0.21 | 0.03 | 0.00 | 0.00 | 0.00 | 0.18 | 0.26 | 0.53 | -0.27 | — |
| Current Ratio | 5.21 | 5.21 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-16.0M | $-16.0M | $-41.3M | $-43.9M | $-31.8M | $-21.2M | $-29.0M | $-29.6M | $-20.8M | $-12.4M | $-5.5M | $-3.1M |
| Returns | ||||||||||||
| ROE | -11.4% | -11.4% | -10.7% | -5.6% | 0.3% | -7.2% | -14.0% | -9.6% | -14.7% | -18.8% | 10.1% | 14.6% |
| Valuation | ||||||||||||
| P/E | — | — | — | — | 722.50 | — | — | — | — | — | — | — |
| P/B | 1.14 | 1.14 | 1.52 | 1.82 | 2.40 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | 15.4% | 15.4% | 37.6% | 21.6% | — | 37.9% | -2.0% | 26.0% | 26.2% | 22.3% | 20.3% | — |
| EPS Growth | -3.0% | -3.0% | -78.3% | -1633.3% | — | 53.8% | -93.6% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.64 → -1.69
Residual
-15.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.